

Maria G Valdovinos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/528601/publications.pdf>

Version: 2024-02-01

29
papers

418
citations

759233

12
h-index

752698

20
g-index

29
all docs

29
docs citations

29
times ranked

298
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating challenging behavior in twins diagnosed with Down syndrome: Measuring treatment integrity and collecting social validity.. Behavior Analysis (Washington, D C), 2023, 23, 60-68.	0.5	0
2	Descriptive Longitudinal Analysis of Stereotypy and Corresponding Changes in Psychotropic Medication. Developmental Neurorehabilitation, 2022, 25, 298-308.	1.1	0
3	Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice. Psychopharmacology, 2021, 238, 1133-1140.	3.1	3
4	Changes in Stereotypical Behavior Following Chlorpromazine Termination: Polypharmacy Effects on Response Class Membership. Advances in Neurodevelopmental Disorders, 2020, 4, 247-252.	1.1	0
5	Psychotropic Medication in Intellectual and Developmental Disabilities: Patterns of Use and Recommendations for Monitoring Effects. Current Developmental Disorders Reports, 2019, 6, 195-201.	2.1	7
6	Characterizing Mood States in Individuals Diagnosed with Bipolar Disorder and Intellectual Disability. Journal of Mental Health Research in Intellectual Disabilities, 2019, 12, 26-44.	2.0	3
7	Evaluating the relationship between the rate and temporal distribution of self-injurious behavior.. Behavior Analysis (Washington, D C), 2019, 19, 72-80.	0.5	0
8	Adverse Side Effects of Psychotropic Medication and Challenging Behavior: Pilot Work Assessing Impact. Journal of Developmental and Physical Disabilities, 2017, 29, 969-982.	1.6	11
9	A review of research on direct-care staff data collection regarding the severity and function of challenging behavior in individuals with intellectual and developmental disabilities. Journal of Intellectual Disabilities, 2016, 20, 296-306.	1.4	6
10	Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. International Journal of Developmental Disabilities, 2016, 62, 200-211.	2.0	20
11	Health Conditions, Learning, and Behavior. Evidence-based Practices in Behavioral Health, 2016, , 1-19.	0.3	0
12	Functional Analysis of Phenotypic Behaviors of a 5-Year-Old Male with Novel 4q21 Microdeletion. Journal of Pediatric Neuropsychology, 2015, 1, 36-41.	0.6	1
13	Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice. Neuroscience Letters, 2015, 585, 109-113.	2.1	14
14	Should clinical trial research of psychotropic medication in autism control for gastrointestinal symptoms?. Journal of Clinical Pharmacology, 2014, 54, 1093-1096.	2.0	0
15	Brief Report: Altered Social Behavior in Isolation-Reared Fmr1 Knockout Mice. Journal of Autism and Developmental Disorders, 2013, 43, 1452-1458.	2.7	15
16	The Use of Reinforcer Assessments in Evaluating Psychotropic Medication Effects. Journal of Developmental and Physical Disabilities, 2012, 24, 515-528.	1.6	9
17	Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome. Journal of Developmental and Physical Disabilities, 2009, 21, 23-37.	1.6	20
18	Social validity of behavioral practices in the treatment of autism—A review of the Super Nanny. Research in Autism Spectrum Disorders, 2009, 3, 173-178.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Using Analogue Functional Analysis to Measure Variations in Problem Behavior Rate and Function After Psychotropic Medication Changes: A Clinical Demonstration. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2009, 2, 279-293.	2.0	23
20	Brief review of current research in FXS: Implications for treatment with psychotropic medication. <i>Research in Developmental Disabilities</i> , 2007, 28, 539-545.	2.2	7
21	Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature. <i>Journal of Autism and Developmental Disorders</i> , 2007, 37, 1883-1901.	2.7	47
22	Blood glucose levels and problem behavior. <i>Research in Developmental Disabilities</i> , 2006, 27, 227-231.	2.2	13
23	Medical and Behavioral Symptoms as Potential Medication Side Effects in Adults With Developmental Disabilities. <i>American Journal on Intellectual and Developmental Disabilities</i> , 2005, 110, 164.	2.4	38
24	Effects of Risperidone on Destructive Behavior of Persons With Developmental Disabilities: III. Functional Analysis. <i>American Journal on Intellectual and Developmental Disabilities</i> , 2004, 109, 310.	2.4	62
25	A behavior-analytic conceptualization of the side effects of psychotropic medication. <i>The Behavior Analyst</i> , 2004, 27, 231-238.	2.5	26
26	Use of functional analysis methodology in the evaluation of medication effects. <i>Journal of Autism and Developmental Disorders</i> , 2003, 33, 271-279.	2.7	48
27	Title is missing!. <i>Journal of Developmental and Physical Disabilities</i> , 2003, 15, 299-334.	1.6	4
28	Prevalence and Correlates of Psychotropic Medication Use among Adults with Developmental Disabilities: 1970-2000. <i>International Review of Research in Mental Retardation</i> , 2003, 26, 175-220.	0.7	16
29	Multimodal evaluation of risperidone for destructive behavior: Functional analysis, direct observations, rating scales, and psychiatric impressions.. <i>Experimental and Clinical Psychopharmacology</i> , 2002, 10, 268-275.	1.8	23